VIDEO: New recommendations made for patients at extreme risk for CVD
PHILADELPHIA — In this Endocrine Today video perspective, Yehuda Handelsman, MD, FACP, MACE, FNLA, medical director and principal investigator of the Metabolic Institute of America in Tarzana, California, discusses new guidelines for the management of dyslipidemia and prevention of CVD.
Lower LDL confers better outcomes, and this is especially true for extreme-risk patients, he said.
“Those extreme-risk patients would be people with diabetes, kidney disease or heterozygous familial hypercholesterolemia,” Handelsman, co-chair of the new American Association of Clinical Endocrinologists/American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of CVD, said. “Their risk for getting another event is so high; that is the group of people who will benefit from combination therapy getting their LDL ... to be below [our recommendation of] 55 mg/dL.”
Also in this patient group are those with LDL below 70 mg/dL who continue to have events, he said.